2. Academic Validation
  3. Discovery of a 1 H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease

Discovery of a 1 H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease

  • J Med Chem. 2025 Oct 23;68(20):21766-21785. doi: 10.1021/acs.jmedchem.5c02124.
Qiangqiang Tao 1 2,  Xixiang Li 1 3 4,  Hongwei Yu 1 2,  Fengming Zou 1 3 4,  Juan Liu 1,  Qingwang Liu 1 3 4,  Aoli Wang 1 3 4,  Chen Hu 1 3 4,  Li Wang 1 3 4 5,  Wenchao Wang 1 2 3 4 5,  Beilei Wang 1 3 4,  Qingsong Liu 1 2 3 4 5,  Jing Liu 1 2 3 4 5
Affiliations

Affiliations

  • 1 Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China.
  • 2 University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
  • 3 Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China.
  • 4 Precision Cancer Medicine Engineering Research Center of Anhui Province, Hefei, Anhui 230088, P. R. China.
  • 5 Primary Cell Engineering Joint Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China.
PMID: 41077763 DOI: 10.1021/acs.jmedchem.5c02124
Abstract

Receptor-interacting protein kinase 1 (RIPK1) undergoes aberrant activation during the process of cell Necroptosis, thereby facilitating and intensifying the inflammatory response. The inhibition of RIPK1 kinase activity is regarded as a promising therapeutic target for immune-mediated inflammatory diseases that are associated with Necroptosis. Herein, we present the structural optimization and investigation into the structure-activity relationship of a series of 1H-pyrazol-3-amine derivatives, derived from the clinical-stage FGFR Inhibitor AZD4547. The prioritized compound 44 displayed low nanomolar activity against RIPK1 and had a potent protective effect against Necroptosis in both human and murine cells in vitro. In addition to high kinome selectivity, the compound also possessed favorable pharmacokinetic properties, with high AUC and oral bioavailability. Furthermore, 44 showed good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS-induced inflammatory bowel disease models in vivo. In summary, 44 is a promising lead compound for RIPK1 inhibition and warrants further study.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z